On Tuesday, Shares of Xerox Corp (NYSE:XRX), gained 0.10% to $9.98.
Xerox Corp, and Mitsubishi Heavy Industries (MHI), both leaders in transportation solutions, recently signed a Memorandum of Understanding to explore, globally, on a case-by-case basis, potential joint Intelligent Transport System (ITS) opportunities.
The parties will focus on electronic toll collection, highway traffic administration, telematics and intelligent urban parking in which Xerox has proficiency in back-end software and operations, predominantly in the Americas and Europe, while MHI has strength in front-end hardware and maintenance, predominantly in Japan and Asia.
Xerox Corporation is engaged in offering business process and document management solutions. The Company operates through the following segments: Services, Document Technology and Other. The Company’s customers include small and midsize businesses (SMBs), graphic communications companies, Governmental entities, educational institutions and Fortune 1000 corporate accounts.
Shares of Horizon Pharma PLC (NASDAQ:HZNP), declined -6.43% to $18.91, during its last trading session.
Horizon Pharma, commented on Proxy Mosaic’s (“Proxy Mosaic”) recommendation in support of Horizon Pharma’s efforts to call two related special meetings of Depomed shareholders to remove and replace all of the current Depomed, Inc. (“Depomed”) directors and to repeal a series of recent amendments to Depomed’s bylaws.
Proxy Mosaic recommended that shareholders of Depomed PROVIDE CONSENT FOR Horizon Pharma’s solicitation for the calling of the special meetings by submitting their WHITE and BLUE proxy cards to Horizon Pharma’s proxy solicitor, MacKenzie Partners, Inc. Proxy Mosaic is the third proxy advisory service to make that recommendation. Horizon Pharma formerly declared that Glass Lewis & Co. and Institutional Shareholder Services had recommended that Depomed shareholders should provide such consent.
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs.
Shares of Aeropostale Inc (NYSE:ARO), declined -3.45% to $0.531, during its last trading session.
Aeropostale, revealed that on September 29, 2015, it received notice from the New York Stock Exchange (the NYSE) that the average closing price of the Company’s common stock over a successive 30 trading-day period had fallen below $1.00 per share, which is the minimum average price required by the NYSE. The notice has no immediate impact on the listing of the Company’s common stock.
The Company plans to notify the NYSE by October 13, 2015 that it intends to cure the deficiency and return to compliance with NYSE continued listing requirements. Under the NYSE rules, the Company can cure this deficiency if, during the six-month period following receipt of the NYSE notice, on the last trading-day of any calendar month, the Company’s common stock has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. If the Company determines that it will cure the stock price deficiency by taking an action that will require approval by its stockholders at the next annual meeting of stockholders, the six-month period described above will extend to shortly after such annual meeting.
The Company intends to consider available alternatives, counting but not limited to, a reverse stock split, in order to cure the stock price deficiency and return to compliance with the NYSE continued listing requirement.
Aeropostale, Inc. is a mall-based, specialty retailer of casual apparel and accessories. The Company operates through two segments: retail stores and e-commerce, and international licensing. It is principally focused on 14 to 17 year-old young women and men through its Aeropostale stores and 4 to 12 year-olds through its P.S. from Aeropostale stores.
Finally, Gannett Co Inc (NYSE:GCI), ended its last trade with -3.29% loss, and closed at $14.40.
Gannett and NYTVF recently declared plans for the StoryNEXT Conference, a full day dedicated to new frontiers and the future of storytelling in the emerging virtual reality space. Supported by the John S. and James L. Knight Foundation, the event will comprise a line-up of panels and keynote conversations tackling production, creative decision-making, advertising, and emerging trends in narrative, non-fiction, and journalistic storytelling across the rapidly-evolving 360° landscape, in addition to a virtual reality experience exhibition featuring hardware demonstrations from Google and HTC, among others. The StoryNEXT Conference will take place on Friday, October 23, as part of the 2015 New York Television Festival.
Two keynote presentations will bookend the conference covering a wide array of virtual reality challenges and opportunities. Wayne Billheimer, Executive Producer for ILMxLAB will headline one presentation while Samsung’s Matt Apfel sits with Sir William Sargent, CEO and Co-Founder of Framestore, for the other. Additional panel topics throughout the day will comprise:
- A Production Primer for Virtual Reality Content
- The Storyteller’s Next Frontier: Content, Coverage and Creative Decision-Making in Virtual Reality
- Aligning Advertising with VR Storytelling
Gannett Co., Inc., formerly Gannett Spinco, Inc., is a media and marketing solutions company. The Company is engaged in providing local content on a range of platforms in the United States. The Company operates through Broadcasting and Digital segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.